{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"171-861-224-013-587","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"171-861-224-013-587"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8759,"type":"PATENT","title":"University of Columbia","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":13487,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8203,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
(a) immobilizing on a solid matrix, a capturing antibody which specifically binds to an early pregnancy associated molecular isoform of hCG, which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(b) contacting the immobilized capturing antibody with a suitable sample from the subject so as to bind the immobilized capturing antibody to the early pregnancy associated molecular isoform of hCG present in the sample, thereby forming a complex;
(c) removing unbound early pregnancy associated molecular isoform of hCG from the complex;
(d) contacting the complex with a detecting antibody which specifically binds to the early pregnancy associated molecular isoform of hCG so as to bind the detecting antibody to the early pregnancy associated molecular isoform of hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B207 (ATCC Designation No. PTA-1626), which detecting antibody does not cross-react with such capturing antibody;
(e) removing unbound detecting antibody from the complex;
(f) measuring the amount of detecting antibody which is bound to the complex so as to thereby determine the amount of early pregnancy associated molecular isoform of hCG in the sample;
(g) determining an amount of early pregnancy associated molecular isoform of hCG in a sample obtained from a temporally-matched normal pregnant subject; and
(h) comparing the amount of the early pregnancy associated molecular isoform of hCG measured in step (f) with the amount determined in step (g), wherein a lower amount of the early pregnancy associated molecular isoform of hCG measured in step (f) compared with step (g) predicts a negative outcome of the pregnancy for the human subject."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["A method of predicting pregnancy outcome in a human subject which comprises:
(a) immobilizing on a solid matrix a capturing antibody which specifically binds to an early pregnancy associated molecular isoform of hCG, which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(b) contacting the immobilized capturing antibody with a first portion of a suitable sample from the subject so as to bind the immobilized capturing antibody to the early pregnancy associated molecular isoform of hCG present in the sample, thereby forming a complex;
(c) removing unbound early pregnancy associated molecular isoform of hCG from the complex;
(d) contacting the complex with a detecting antibody which specifically binds to the early pregnancy associated molecular isoform of hCG so as to bind the detecting antibody to the early pregnancy associated molecular isoform of hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B207 (ATCC Designation No. PTA-1626), which detecting antibody does not cross-react with a capturing antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(e) removing unbound detecting antibody from the complex;
(f) measuring the amount of detecting antibody which is bound to the complex so as to thereby determine the amount of early pregnancy associated molecular isoform of hCG in the sample;
(g) immobilizing on a solid matrix, a capturing antibody which specifically binds to intact non-nicked hCG, which isoform is recognized by the antibody produced by hybridoma cell line B109 (ATCC Designation No. PTA-1624);
(h) contacting the immobilized capturing antibody with a second portion of the suitable sample so as to bind the immobilized capturing antibody to the intact non-nicked hCG present in the sample, thereby forming a complex;
(i) removing unbound intact non-nicked hCG from the complex;
(j) contacting the complex with a detecting antibody which specifically binds to intact non-nicked hCG so as to bind the detecting antibody to the intact non-nicked hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B108 (ATCC Designation No. PTA-1625), which detecting antibody does not cross-react with a capturing antibody produced by hybridoma cell line B109 (ATCC Designation No. PTA-1624);
(k) removing unbound detecting antibody from the complex;
(l) measuring the amount of detecting antibody which is bound to the complex so as to thereby determine the amount of non-nicked hCG in the sample;
(m) comparing the amount of antibody measured in step (f) with the amount of antibody measured in step (l) so as to thereby determine a ratio of the amount of antibody measured in step (f) to the amount of antibody measured in step (l);
(n) repeating steps (a) through (m) and determining a pattern of the ratios measured; and
(o) comparing the pattern of ratios determined in step (n) with that of a normal pregnant subject, wherein a pattern of higher ratios determined in step (n) compared with that of the normal pregnant subject indicates a negative outcome of the pregnancy and a pattern of lower ratios determined in step (n) compared with that of the normal pregnant subject indicates a positive outcome of the pregnancy."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2 , wherein steps (g) through (l) are performed prior to steps (a) through (f)."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A method of predicting pregnancy outcome in a human subject which comprises:
(a) contacting a suitable sample from the subject with a capturing antibody which specifically binds to an early pregnancy associated molecular isoform of hCG so as to bind the capturing antibody to the early pregnancy associated molecular isoform of hCG present in the sample, thereby forming a complex, which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(b) removing unbound capturing antibody and unbound early pregnancy associated molecular isoform of hCG from the complex;
(c) contacting the complex with a detecting antibody which specifically binds to the early pregnancy associated molecular isoform of hCG so as to bind the detecting antibody to the early pregnancy associated molecular isoform of hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B207 (ATCC Designation No. PTA-1626), which detecting antibody does not cross-react with such capturing antibody;
(d) removing unbound detecting antibody from the complex;
(e) measuring the amount of detecting antibody which is bound to the complex so as to thereby determine the amount of early pregnancy associated molecular isoform of hCG in the sample;
(f) determining an amount of the early pregnancy associated molecular isoform of hCG in a sample obtained from a temporally-matched normal pregnant subject; and
(g) comparing the amount the early pregnancy associated molecular isoform of hCG measured in step (e) with the amount determined in step (f), wherein a lower amount measured in step (e) compared with step (f) predicts a negative outcome of the pregnancy for the human subject."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method of predicting pregnancy outcome in a human subject which comprises:
(a) contacting a first portion of a suitable sample from the subject with a capturing antibody which specifically binds to an early pregnancy associated molecular isoform of hCG so as to bind the capturing antibody to the early pregnancy associated molecular isoform of hCG present in the sample, thereby forming a complex, which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(b) removing unbound capturing antibody and unbound early pregnancy associated molecular isoform of hCG from the complex;
(c) contacting the complex with a detecting antibody which specifically binds to the early pregnancy associated molecular isoform of hCG so as to bind the detecting antibody to the early pregnancy associated molecular isoform of hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467), which detecting antibody does not cross-react with a capturing antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467);
(d) removing unbound detecting antibody from the complex;
(e) measuring the amount of detecting antibody which binds to the complex so as to thereby determine the amount of early pregnancy associated molecular isoform of hCG present in the sample;
(f) contacting a second portion of the sample with a capturing antibody which specifically binds to intact non-nicked hCG so as to bind the capturing antibody to the intact non-nicked hCG present in the sample, thereby forming a complex, which isoform is recognized by the antibody produced by hybridoma cell line B109 (ATCC Designation No. PTA-1624);
(g) removing unbound capturing antibody and unbound intact non-nicked hCG from the complex;
(h) contacting the complex with a detecting antibody which specifically binds to intact non-nicked hCG so as to bind the detecting antibody to the intact non-nicked hCG in the complex, which isoform is recognized by the antibody produced by hybridoma cell line B108 (ATCC Designation No. PTA-1625), which detecting antibody does not cross-react with a capturing antibody produced by hybridoma cell line B109 (ATCC Designation No. PTA-1624);
(i) removing unbound detecting antibody from the complex;
(j) measuring the amount of detecting antibody which is bound to the complex so as to thereby determine the amount of intact non-nicked hCG present in the sample;
(k) comparing the amount of antibody measured in step (e) with the amount of antibody measured in step (j) so as to thereby determine a ratio of the amount of antibody measured in step (e) to the amount of antibody measured in step (j);
(l) repeating steps (a) through (k) so as to determine a pattern of the ratios measured; and
(m) comparing the pattern of ratios determined in step (l) with that of a normal pregnant subject, wherein a pattern of higher ratios determined in step (l) compared with that of the normal pregnant subject indicates a negative outcome of the pregnancy and a pattern of lower ratios determined in step (l) compared with that of the normal pregnant subject indicates a positive outcome of the pregnancy."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5 , wherein steps (f) through (j) are performed prior to steps (a) through (e)."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 , 2 , 4 , and 5 , wherein the detecting antibody is labeled with a detectable marker."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7 , wherein the detectable marker is a radioactive label, enzyme, dye, magnetic bead, or biotin."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8 , wherein the detectable marker is a radioactive label and the radioactive label is I 125 ."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 , 2 , 4 and 5 wherein the sample is a urinary sample."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 , 2 , 4 , and 5 , wherein the sample is an aggregate of samples obtained from the subject on at least two consecutive days and then combined to form an aggregate sample for testing."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 , 2 , 4 and 5 wherein the sample is a blood sample."],"number":12,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}